Publicité
Œuvres citées
Œuvres citées
Ahmadi, M, and Q Q Rodrigo. 2013. "Automatic denoising of single-trial evoked potentials."
NeuroImage:672-680.
Audo, I., M. Michaelides, A. G. Robson, M. Hawlina, V. Vaclavik, J. M. Sandbach, M. M.
Neveu, C. R. Hogg, D. M. Hunt, A. T. Moore, A. C. Bird, A. R. Webster, and G. E.
Holder. 2008. "Phenotypic variation in enhanced S-cone syndrome." Invest
Ophthalmol Vis Sci 49 (5) :2082-93. doi : 10.1167/iovs.05-1629.
Berson, EL. 1993. « Retinitis pigmentosa : The Friedenwald Lecture. » Investigative
Ophthalmology and Visual Science 34 :1659-1673.
Brigell, M. G., B. Chiang, A. Y. Maa, and C. Q. Davis. 2020. "Enhancing Risk Assessment in
Patients with Diabetic Retinopathy by Combining Measures of Retinal Function and
Structure." Transl Vis Sci Technol 9 (9) :40. doi : 10.1167/tvst.9.9.40.
Centers for Disease Control and Prevention. 2011. National Diabetes Fact Sheet, 2011.
edited by US Department of Health and Human Services, Centers for Disease Control
and Prevention.
Cideciyan, A, and S Jacobson. 1996. "An alternative phototransduction model for human rod
and cone ERG a-waves: normal parameters and variation with age." Vision
Res :2609-21.
Cideciyan, A. V., and S. G. Jacobson. 1993. "Negative electroretinograms in retinitis
pigmentosa." Invest Ophthalmol Vis Sci 34 (12) :3253-63.
CLSI. 2008. Guideline for Defining, Establishing, and Verifying Reference Intervals in the
Clinical Laboratory; Approved Guideline—Third Edition. CLSI Document EP28-A3c.
Wayne, PA: Clinical and Laboratory Standards Institute.
Davis, C. Q., and R. Hamilton. 2021. "Reference ranges for clinical electrophysiology of
vision." Doc Ophthalmol. doi : 10.1007/s10633-021-09831-1.
Davis, C. Q., O. Kraszewska, and C. Manning. 2017. "Constant luminance (cd.s/m2) versus
constant retinal illuminance (Td.s) stimulation in flicker ERGs." Doc Ophthalmol. doi :
10.1007/s10633-017-9572-3.
Davis, M. D., M. R. Fisher, R. E. Gangnon, F. Barton, L. M. Aiello, E. Y. Chew, F. L. Ferris, 3rd,
and G. L. Knatterud. 1998. "Risk factors for high-risk proliferative diabetic
retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study
Report #18." Invest Ophthalmol Vis Sci 39 (2) :233-52.
Degirmenci, M. F. K., S. Demirel, F. Batioglu, and E. Ozmert. 2018. "Role of a mydriasis-free,
full-field flicker ERG device in the detection of diabetic retinopathy." Doc
Ophthalmol 137 (3) :131-141. doi : 10.1007/s10633-018-9656-8.
FDA Advisory Committee. 2009. Sabril® (vigabatrin) for Oral Solution for Infantile Spasms.
Fishman, G A, D G Birch, G E Holder, and M G Brigell. 2001. Electrophysiologic Testing : The
Foundation of the American Academy of Ophthalmology.
RETeval Manuel de l'utilisateur de l'appareil
80
Publicité
